Tandem Diabetes Care (TNDM) Stock Analysis & AI Equity Report

Medical - Devices USD Explore free reports

Tandem Diabetes Care (TNDM) overview

Tandem Diabetes Care (TNDM) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 1,015m and operating profit of USD -187m; the year-end share price was 21.98 USD and market capitalisation was USD 1,501m. Tandem Diabetes Care is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Tandem Diabetes Care's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 155mFY 2025
Share price21.98 USDFY 2025 year end
RevenueUSD 1,015mFY 2025
Operating profitUSD -187mFY 2025
Net earningsUSD -205mFY 2025
Market capitalisationUSD 1,501mFY 2025 year end

About Tandem Diabetes Care

Tandem Diabetes Care designs, develops, and commercializes insulin delivery systems and diabetes technology for people with insulin-dependent diabetes. Its portfolio includes t:slim X2 and Tandem Mobi pump platforms, both featuring Control-IQ+ hybrid closed-loop technology, alongside applications and insights. The company serves people living with diabetes in more than 25 countries.

Generate the Tandem Diabetes Care report

Tandem Diabetes Care is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Tandem Diabetes Care and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Tandem Diabetes Care

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.